AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
SAN ANTONIO -- The investigational OncoVue breast cancer risk test provided a 2.4-fold improvement over the Gail model in accurately identifying women at elevated risk of breast cancer in a blinded validation study.
This is the third independent study demonstrating that the OncoVue individualized breast cancer risk estimator outperforms the widely used Gail model, Dr. Kathie M. Dalessandri said at the San Antonio Breast Cancer Symposium.
OncoVue (InterGenetics Inc. of Oklahoma City) integrates genetic testing for 22 single nucleotide polymorphism variants located on 19 genes with classic Gail model personal risk factors, such as age at first menses and first live birth and the number of first-degree relatives having breast cancer.
The genetic test uses DNA from a saliva sample, explained Dr. Dalessandri of the University of California, San Francisco, and the Buck Institute for Age Research in Novato, Calif.
She reported on 169 women diagnosed ...
Source: HighBeam Research, OncoVue breast cancer risk test outperforms Gail model.(NEWS)